A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity

Biochemistry

Volumn 46, Issue 32, 2007, Pages 9199-9207

  Fromme, Raimund ^a   Katiliene, Zivile ^a   Giomarelli, Barbara ^b   Bogani, Federica ^a   Mc Mahon, James ^b   Mori, Toshiyuki ^b,c   Fromme, Petra ^a   Ghirlanda, Giovanna ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBIOTICS; BINDING ENERGY; CARBOHYDRATES; MOLECULAR INTERACTIONS; MUTAGENESIS;

ANTIVIRAL ACTIVITY; CARBOHYDRATE-BINDING DOMAINS; CYANOBACTERIAL LECTIN; OLIGOMANNOSIDES;

PROTEINS;

AMINO ACID; CARBOHYDRATE; CYANOVIRIN N; DIMER; GLYCOPROTEIN GP 120; LECTIN; MANNOSIDE; MONOMER; MUTANT PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; CYANOBACTERIUM; HUMAN IMMUNODEFICIENCY VIRUS; HYDROGEN BOND; IN VITRO STUDY; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN ENGINEERING;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; BACTERIAL PROTEINS; BINDING SITES; CARBOHYDRATES; CARRIER PROTEINS; CRYSTALLOGRAPHY, X-RAY; HIV ENVELOPE PROTEIN GP120; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; TETRAZOLIUM SALTS; THERMODYNAMICS;

CYANOBACTERIA;

EID: 34547916495     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi700666m     Document Type: Article

References (45)

1. Boyd, M. R., Gustafson, K. R., McMahon, J. B., Shoemaker, R. H., O'Keefe, B. R., Mori, T., Gulakowski, R. J., Wu, L., Rivera, M. I., Laurencot, C. M., Currens, M. J., Cardellina, II, J. H., Buckheit, R. W., Jr., Nara, P. L., Pannell, L. K., Sowder, R. C., II, and Henderson, L. E. (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development, Antimicrob. Agents Chemother. 41, 1521-1530.
2. O'Keefe, B. R., Smee, D. F., Turpin, J. A., Saucedo, C. J., Gustafson, K. R., Mori, T., Blakeslee, D., Buckheit, R., and Boyd, M. R. (2003) Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin, Antimicrob. Agents Chemother. 47, 2518-2525.
3. Helle, F., Wychowski, C., Vu-Dac, N., Gustafson, K. R., Voisset, C., and Dubuisson, J. (2006) Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans, J. Biol. Chem. 281, 25177-25183.
4. Barrientos, L. G., and Gronenborn, A. M. (2005) The highly specific carbohydrate-binding protein cyanovirin-N: structure, anti-HIV/Ebola activity and possibilities for therapy, Mini Rev. Med. Chem. 5, 21-31.
5. De Clercq, E. (2005) Emerging anti-HIV drugs, Expert Opin. Emerg. Drugs 10, 241-273.
6. Reeves, J. D., and Piefer, A. J. (2005) Emerging drug targets for antiretroviral therapy, Drugs 65, 1747-1766.
7. Dey, B., Lerner, D. L., Lusso, P., Boyd, M. R., Elder, J. H., and Berger, E. A. (2000) Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses, J. Virol. 74, 4562-4569.
8. Esser, M. T., Mori, T., Mondor, I., Sattentau, Q. J., Dey, B., Berger, E. A., Boyd, M. R., and Lifson, J. D. (1999) Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120, J. Virol. 73, 4360-4371.
9. Barrientos, L. G., O'Keefe, B. R., Bray, M., Sanchez, A., Gronenborn, A. M., and Boyd, M. R. (2003) Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus, Antiviral Res. 58, 47-56.
10. Botos, I., and Wlodawer, A. (2003) Cyanovirin-N: a sugar-binding antiviral protein with a new twist, Cell. Mol. Life Sci. 60, 277- 287.
11. Bewley, C. A., Gustafson, K. R., Boyd, M. R., Covell, D. G., Bax, A., Clore, G. M., and Gronenborn, A. M. (1998) Solution structure of cyanovirin-N, a potent HIV-inactivating protein, Nat. Struct. Biol. 5, 571-578.
12. Bewley, C. A. (2001) Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120, Structure (Cambridge) 9, 931-940.
13. Botos, I., O'Keefe, B. R., Shenoy, S. R., Cartner, L. K., Ratner, D. M., Seeberger, P. H., Boyd, M. R., and Wlodawer, A. (2002) Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides, J. Biol. Chem. 277, 34336-34342.
14. Yang, F., Bewley, C. A., Louis, J. M., Gustafson, K. R., Boyd, M. R., Gronenborn, A. M., Clore, G. M., and Wlodawer, A. (1999) Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping, J. Mol. Biol. 288, 403-412.
15. Shenoy, S. R., Barrientos, L. G., Ratner, D. M., O'Keefe, B. R., Seeberger, P. H., Gronenborn, A. M., and Boyd, M. R. (2002) Multisite and multivalent binding between cyanovirin-N and branched oligomannosides: calorimetric and NMR characterization, Chem. Biol. 9, 1109-1118.
16. Liu, Y., and Eisenberg, D. (2002) 3D domain swapping: as domains continue to swap, Protein Sci. 11, 1285-1299.
17. Bennett, M. J., Choe, S., and Eisenberg, D. (1994) Domain swapping: entangling alliances between proteins, Proc. Natl. Acad. Sci. U.S.A. 91, 3127-3131.
18. Barrientos, L. G., Lasala, F., Delgado, R., Sanchez, A., and Gronenborn, A. M. (2004) Flipping the switch from monomelic to dimeric CV-N has little effect on antiviral activity, Structure (Cambridge) 12, 1799-1807.
19. Barrientos, L. G., and Gronenborn, A. M. (2002) The domain-swapped dimer of cyanovirin-N contains two sets of oligosaccharide binding sites in solution, Biochem. Biophys. Res. Commun. 298, 598-602.
20. Barrientos, L. G., Louis, J. M., Botos, I., Mori, T., Han, Z., O'Keefe, B. R., Boyd, M. R., Wlodawer, A., and Gronenborn, A. M. (2002) The domain-swapped dimer of cyanovirin-N is in a metastable folded state: reconciliation of X-ray and NMR structures, Structure 10, 673-686.
21. Mori, T., Barrientos, L. G., Han, Z., Gronenborn, A. M., Turpin, J. A., and Boyd, M. R. (2002) Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts, Protein Expression Purif. 26, 42-49.
22. Kelley, B. S., Chang, L. C., and Bewley, C. A. (2002) Engineering an obligate domain-swapped dimer of cyanovirin-N with enhanced anti-HIV activity, J. Am. Chem. Soc. 124, 3210-3211.
23. Bertozzi, C. R., and Kiessling, L. L. (2001) Chemical glycobiology, Science 291, 2357-2364.
24. Ziolkowska, N. E., O'Keefe, B. R., Mori, T., Zhu, C., Giomarelli, B., Vojdani, F., Palmer, K. E., McMahon, J. B., and Wlodawer, A. (2006) Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding, Structure 14, 1127-1135.
25. Williams, D. C., Jr., Lee, J. Y., Cai, M., Bewley, C. A., and Clore, G. M. (2005) Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man3GlcNAc2: structural basis for specificity and high-affinity binding to the core pentasaccharide from N-linked oligomannoside, J. Biol. Chem. 280, 29269-29276.
26. Chang, L. C., and Bewley, C. A. (2002) Potent inhibition of HIV-1 fusion by cyanovirin-N requires only a single high affinity carbohydrate binding site: characterization of low affinity carbohydrate binding site knockout mutants, J. Mol. Biol. 318, 1-8.
27. Barrientos, L. G., Matei, E., Lasala, F., Delgado, R., and Gronenborn, A. M. (2006) Dissecting carbohydrate-cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition, Protein Eng., Des. Sel. 19, 525-535.
28. Botos, I., Mori, T., Cartner, L. K., Boyd, M. R., and Wlodawer, A. (2002) Domain-swapped structure of a mutant of cyanovirin-N, Biochem. Biophys. Res. Commun. 294, 184-190.
29. Vaguine, A. A., Richelle, J., and Wodak, S. J. (1999) SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model, Acta Crystallogr., Sect. D: Biol. Crystallogr. 55, 191-205.
30. Delano, W. L. (2005) Delano Scientific, LLC, South San Francisco, CA.
31. Margulis, C. J. (2005) Computational study of the dynamics of mannose disaccharides free in solution and bound to the potent anti-HIV virucidal protein cyanovirin, J. Phys. Chem. B 109, 3639-3647.
32. Blixt, O., Head, S., Mondala, T., Scanlan, C., Huflejt, M. E., Alvarez, R., Bryan, M. C., Fazio, F., Calarese, D., Stevens, J., Razi, N., Stevens, D. J., Skehel, J. J., van Die, I., Burton, D. R., Wilson, I. A., Cummings, R., Bovin, N., Wong, C. H., and Paulson, J. C. (2004) Printed covalent glycan array for ligand profiling of diverse glycan binding proteins, Proc. Natl. Acad. Sci. U.S.A. 101, 17033-17038.
33. Barrientos, L. G., Louis, J. M., Hung, J., Smith, T. H., O'Keefe, B. R., Gardella, R. S., Mori, T., Boyd, M. R., and Gronenborn, A. M. (2002) Design and initial characterization of a circular permuted variant of the potent HIV-inactivating protein cyanovirin-N, Proteins 46, 153-160.
34. O'Keefe, B. R., Shenoy, S. R., Xie, D., Zhang, W., Muschik, J. M., Currens, M. J., Chaiken, I., and Boyd, M. R. (2000) Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41, Mol. Pharmacol. 58, 982-992.
35. Nussbaum, O., Broder, C. C., and Berger, E. A. (1994) Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation, J. Virol. 68, 5411-5422.
36. Gulakowski, R. J., McMahon, J. B., Staley, P. G., Moran, R. A., and Boyd, M. R. (1991) A semiautomated multiparameter approach for anti-HIV drug screening, J. Virol. Methods 33, 87-100.
37. Mori, T., Gustafson, K. R., Pannell, L. K., Shoemaker, R. H., Wu, L., McMahon, J. B., and Boyd, M. R. (1998) Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium, Protein Expression Purif. 12, 151-158.
38. Collaborative Computational Project, Number 4 (1994) The CCP4 Suite - Programs for Protein Crystallography, Acta Crystallogr., Sect. D: Biol. Crystallogr. 50, 760-763.
39. Minor, W., Cymborowski, M., Otwinowski, Z., and Chruszcz, M. (2006) HKL-3000: the integration of data reduction and structure solution - from diffraction images to an initial model in minutes, Acta Crystallogr., Sect. D: Biol. Crystallogr. 62, 859-866.
40. Otwinowski, Z., and Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode, Macromol. Crystallogr., Part A 276, 307-326.
41. McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C., and Read, R. J. (2005) Likelihood-enhanced fast translation functions, Acta Crystallogr., Sect. D: Biol. Crystallogr. 61, 458-464.
42. Perrakis, A., Morris, R., and Lamzin, V. S. (1999) Automated protein model building combined with iterative structure refinement, Nat. Struct. Biol. 6, 458-463.
43. Perrakis, A., Harkiolaki, M., Wilson, K. S., and Lamzin, V. S. (2001) ARP/wARP and molecular replacement, Acta Crystallogr., Sect. D: Biol. Crystallogr. 57, 1445-1450.
44. McRee, D. E. (1999) XtalView Xfit - A versatile program for manipulating atomic coordinates and electron density, J. Struct. Biol. 125, 156-165.
45. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method, Acta Crystallogr., Sect. D: Biol. Crystallogr. 53, 240-255.